Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sight Sciences, Inc. (Nasdaq: SGHT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an eyecare technology company focused on interventional glaucoma and dry eye devices, Sight Sciences uses SEC reports to communicate financial results, capital arrangements, and key corporate developments.
Investors can review Form 8-K filings where the company reports quarterly and year-to-date financial highlights, raises or updates revenue and adjusted operating expense guidance, and describes restructuring plans intended to reduce operating expenses and improve cost efficiencies. Other 8-Ks detail amendments to the company’s senior secured term loan facility with Hercules Capital, including changes to the interest-only period and tranche availability.
Filings also disclose material corporate events such as workforce reductions, executive transitions, and board changes. For example, the company has reported promotions of senior executives, entry into amended and restated employment agreements, and the resignation of directors, along with related compensation and severance terms.
These SEC documents complement the company’s press releases on clinical and reimbursement milestones for its OMNI® Surgical System, SION® Surgical System, and TearCare® System. On Stock Titan, users can access real-time updates from EDGAR and use AI-powered summaries to quickly understand the main points of lengthy filings, including quarterly (10-Q) and annual (10-K) reports when available, as well as Form 4 insider transaction reports.
AI-generated overviews help explain complex sections of Sight Sciences’ filings in plain language, highlight changes in guidance or capital structure, and point out disclosures that may be relevant to the company’s Surgical Glaucoma and Dry Eye segments. This allows readers to navigate detailed regulatory documents more efficiently while focusing on the aspects of SGHT’s business that matter most to them.
Sight Sciences announced that two Medicare Administrative Contractors, Novitas and FCSO, established jurisdiction-wide pricing for CPT 0563T, which describes the TearCare procedure. The Medicare fee schedule amount is $1,141.59, effective for dates of service on and after January 1, 2025, across all Novitas and FCSO jurisdictions.
The local fee schedules are active for claim processing and are expected to be posted on the Novitas and FCSO websites. TearCare claims in these areas will be payable based on individual medical necessity determinations. The regions covered by these MACs have an estimated 10.4 million total covered lives. The company also posted an investor presentation and plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call.
Sight Sciences, Inc. reporting person Brenton Taylor disclosed a sale of 591 shares of common stock on 10/06/2025. The sale was executed to cover the reporting person's tax liability related to the vesting of restricted stock units and occurred in multiple transactions at prices ranging from $3.32 to $3.45, with a weighted average price of $3.37. After the reported sale, the reporting person beneficially owned 185,249 shares, held directly. The form bears a signature date of 10/08/2025.
Sight Sciences, Inc. filing a Form 144 reports a proposed sale of 591 common shares with an aggregate market value of $1,992.32. The seller acquired these shares on 09/30/2025 through restricted stock vesting and the payment type is listed as compensation. The proposed approximate sale date is 10/06/2025 on NASDAQ. The filing shows 52,367,359 shares outstanding for the issuer and indicates no sales by the seller in the past three months. The filer attests there is no undisclosed material adverse information and includes the standard signature and legal notice language.
Sight Sciences (SGHT) disclosed an insider transaction by its Chief Financial Officer. On 10/02/2025, the officer reported a sale of 19,948 shares of common stock at $3.3 per share, coded “S.” Following the transaction, the officer directly holds 597,520 shares.
The filing notes the shares were sold to cover the reporting person’s tax liability associated with the vesting of restricted stock units. This reflects a routine tax-related disposition rather than a discretionary portfolio trade.
Sight Sciences (SGHT) President & CEO, Director, and 10% owner Paul Badawi reported a sale of common stock on 10/01/2025. He sold 24,441 shares at $3.34 per share (Code S), as noted in the filing’s footnote, to cover tax liabilities arising from the vesting of restricted stock units.
Following this transaction, Badawi beneficially owns 5,962,502 shares of Sight Sciences common stock directly. The filing indicates the disposition was related to tax withholding tied to equity compensation vesting.
David Badawi, Chief Technology Officer and director of Sight Sciences, Inc. (SGHT), reported a sale of 6,033 shares of common stock on 10/03/2025 at a price of $3.27 per share. The filing states the shares were sold to cover the reporting person's tax liability from the vesting of restricted stock units. After the sale, Mr. Badawi beneficially owned 1,864,992 shares of common stock.
This Form 144 for Sight Sciences, Inc. (SGHT) notifies a proposed sale of 9,731 common shares held at Fidelity Brokerage Services LLC with an aggregate market value of $31,848.59, with an approximate sale date of 10/03/2025. The shares were acquired on 09/30/2025 through restricted stock vesting and the acquisition payment is listed as compensation. The filing also discloses a prior sale by Jeremy Hayden of 9,160 common shares on 07/03/2025 for gross proceeds of $38,235.67. The filer represents, by signing, that they are not aware of any undisclosed material adverse information about the issuer.
Form 144 filing: A shareholder filed a notice to sell up to 15,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 10/03/2025. The filing lists an aggregate market value of $49,276.20 for the proposed sale.
The shares were acquired via restricted stock vesting: 11,236 shares on 10/17/2024 and 3,764 shares on 10/18/2024, recorded as compensation. Shares outstanding were 52,367,359 at the time cited.
Recent activity over the past three months shows sales by Matthew Link of common stock: 10,000 shares for $35,227.21 on 09/12/2025; 15,990 shares for $55,291.81 on 09/16/2025; 20,000 shares for $73,400.00 on 09/19/2025; and 20,753 shares for $73,350.73 on 09/23/2025.
Sight Sciences, Inc. (SGHT) Form 144 summary: The filing notifies a proposed sale of 19,948 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $65,750.60. The sale is scheduled for 10/02/2025 on NASDAQ and the issuer reports 52,367,359 shares outstanding. The shares were acquired on 09/30/2025 through restricted stock vesting and were recorded as compensation. The filer also disclosed a prior sale of 19,260 shares on 07/02/2025 that generated $78,933.26 in gross proceeds. The notice includes the standard signature representation that the seller is unaware of undisclosed material adverse information.
Sight Sciences, Inc. (SGHT) Form 144 filing reports a proposed sale of 24,441 common shares through Fidelity Brokerage Services LLC on Nasdaq. The shares were acquired by restricted stock vesting on 09/30/2025 and are identified as compensation. The filer reports 52,367,359 shares outstanding for the class, and records an approximate aggregate market value of $81,740.48 for the shares to be sold with an approximate sale date of 10/01/2025. The filing also discloses that Paul Badawi sold 23,637 common shares on 07/01/2025 for gross proceeds of $98,133.73. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.